Molecular pathology of colorectal carcinoma. A systematic review centred on the new role of the Pathologist

Pathologica

Volumn 104, Issue 6, 2012, Pages 432-441

  Remo, A ^a   Pancione, M ^b   Zanella, C ^a   Vendraminelli, R ^a  

^a Mater Salutis Hospital   (Italy)

^b UNIVERSITY OF SANNIO   (Italy)

Author keywords

CIMP; CIN; Colorectal carcinoma; Molecular biology; MSI; Pathologist

Indexed keywords

CARCINOMA; CHROMATIN ASSEMBLY AND DISASSEMBLY; COLON; COLORECTAL TUMOR; EPITHELIAL MESENCHYMAL TRANSITION; HUMAN; PATHOLOGY; PHYSICIAN ATTITUDE; REVIEW;

CARCINOMA; CHROMATIN ASSEMBLY AND DISASSEMBLY; COLON; COLORECTAL NEOPLASMS; EPITHELIAL-MESENCHYMAL TRANSITION; HUMANS; PATHOLOGY; PHYSICIAN'S ROLE;

EID: 84872898597     PISSN: 00312983     EISSN: 1591951X     Source Type: Journal    
DOI: None     Document Type: Review

References (86)

1. Zavoral M, Suchanek S, Zavada F, et al. Colorectal cancer screening in Europe. World J Gastroenterol 2009; 15:5907-15.
2. Bosman FT, Carneiro F, Hruban RH, et al. WHO classification of Tumours of the digestive system. Lyon, France: IARC Press 2002.
3. Stang A, Kluttig A. Etiologic insights from surface adjustment of colorectal carcinoma incidences: An analysis of the U.S. SEER data 2000-2004. Am J Gastroenterol 2008;103:2853-61.
4. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer Journal for Clinicians 2008;58:71-96.
5. Sung JJY, Lau JYW, Goh KL, et al. Increasing incidence of colorectal cancer in Asia: Implications for screening. Lancet Oncol 2005;6:871-6.
6. Edwards BK, Ward E, Kohler BA, et al. Annual report to the nation the status of cancer, 1975-2006, featuring colorectal cancer trends and impact of interventions (risk factors, screening, and treatment) to reduce future rates. Cancer 2010;116:544-73.
7. Beckman RA, Loeb LA. Genetic instability in cancer: Theory and experiment. Semin Cancer Biol 2005;15:423-35.
8. Tenesa A, Dunlop MG. New insights into the aetiology of colorectal cancer from genome-wide association studies. Nat Rev Genet 2009;10:353-8.
9. Rustgi AK. The genetics of hereditary colon cancer. Genes Dev 2007;21:2525-38.
10. Yosry A. Schistosomiasis and neoplasia. Contrib Microbiol 2006;13:81-100.
11. Rapiti E, Fioretta G, Verkooijen H, et al. Increased risk of colon cancer after external radiation therapy for prostate cancer. Int J Cancer 2008;123:1141-5.
12. Gobet R. Alternative management of bladder exstrophy. Curr Opin Urol 2009;19:424-6.
13. Pancione M, Remo A, Colantuoni V. Genetic and epigenetic events generate multiple pathways in colorectal cancer progression. Patholog Res Int 2012;2012:509348.
14. Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 1990;61:759-67.
15. Smith G, Carey FA, Beattie J, et al. Mutations in APC, Kirsten-ras, and p53-alternative genetic pathways to colorectal cancer. Proc Natl Acad Sci USA 2002;99:9433-8.
16. Ogino S, Goel A. Molecular classification and correlates in colorectal cancer.J Mol Diagn 2008;10:13-27.
17. Jass Jr. Classification of colorectal cancer based on correlation of clinical,morphological and molecular features. Histopathology 2007;50:113-30.
18. Markowitz SD, Bertagnolli MM. Molecular basis of colorectal cancer. N Engl J Med 2009;361:2404-60.
19. Young J, Jenkins M, Parry S, et al. Serrated pathway colorectal cancer in the population: Genetic consideration. Gut 2007;56:1453-9.
20. Sharma S, Kelly TK, Jones PA. Epigenetics in cancer. Carcinogenesis 2009;31:27-36.
21. Esteller M. Molecular origins of cancer: Epigenetics in cancer. N Engl J Med 2008;358:1148-96.
22. Bonasio R, Tu S, Reinberg D. Molecular signals of epigenetic states. Science 2010;330:612-6.
23. Hanahan D, Weinberg RA. Hallmarks of cancer: The next generation. Cell 2011;144:646-74.
24. Boland CR, Komarova NL, Goel A. Chromosomal instability and cancer: Not just one CINgle mechanism. Gut 2009;58:163-4.
25. Pino MS, Chung DC. The chromosomal instability pathway in colon cancer. Gastroenterology 2010;138:2059-72.
26. Fearon ER. Molecular genetics of colorectal cancer. Annu Rev Pathol 2011;6:479-507.
27. Walther A, Houlston R, Tomlinson I. Association between chromosomal instability and prognosis in colorectal cancer: A metaanalysis. Gut 2008;57:941-50.
28. Boland CR, Goel A. Microsatellite instability in colorectal cancer. Gastroenterology 2010;138:2073-87.
29. Loeb LA, Springgate CF, Battula N. Errors in DNA replication as a basis of malignant changes. Cancer Res 1974;34:2311-21.
30. Klein CA. Random mutations, selected mutations: A PIN opens the door to new genetic landscapes. Proc Natl Acad Sci USA 2006;103:18033-4.
31. Issa JPJ, Shen L, Toyota M. CIMP, at last. Gastroenterology 2005;129:1121-4.
32. Toyota M, Ahuja N, Ohe-Toyota, et al. CpG island methylator phenotype in colorectal cancer. Proc Natl Acad Sci USA 1999;96:8681-6.
33. Samowitz WS, Albertsen H, Herrick J, et al. Evaluation of a large, population-based sample supports a CpG island methylator phenotype in colon cancer. Gastroenterology 2005;129:837-45.
34. Curtin K, Slattery ML, Samowitz WS. CpG island methylation in colorectal cancer: Past, present and future. Patholog Res Int 2011;2011:902674.
35. Cancer Genome Atlas Network. Comprehensive molecular characterization of human colon and rectal cancer. Nature 2012;7407:330-7.
36. Issa JP. Colon cancer: It's CIN or CIMP. Clin Cancer Res 2008;14:5939-40.
37. Shih IM, Wang TL, Traverso G, et al. Top-down morphogenesis of colorectal tumors. Proc Natl Acad Sci USA 2001;98:2640-5.
38. Feinberg AP, Ohlsson R, Henikoff S. The epigenetic progenitor origin of human cancer. Nat Rev Genet 2006;7:21-33.
39. Irizarry RA, Ladd-Acosta C, Wen B, et al. The human colon cancer methylome shows similar hypo-and hypermethylation at conserved tissue-specific CpG island shores. Nat Genet 2009;41:178-86.
40. Ohm JE, McGarvey KM, Yu X, et al. A stem cell-like chromatin pattern may predispose tumor suppressor genes to DNA hypermethylation and heritable silencing. Nat Genet 2007;39:237-42.
41. Mohammad HP, Cai Y, McGarvey KM, et al. Polycomb CBX7 promotes initiation of heritable repression of genes frequentlysilenced with cancer-specific DNA hypermethylation. Cancer Res 2009;69:6322-30.
42. Snover DC. Update on the serrated pathway to colorectal carcinoma. Hum Pathol 2011;42:1-10.
43. Leggett B, Whitehall V. Role of the serrated pathway in colorectal cancer pathogenesis. Gastroenterology 2010;138:2088-100.
44. Dieter SM, Ball CR, Hoffmann CM, et al. Distinct types of tumorinitiating cells for human colon cancer tumors and metastases. Cell Stem Cell 2011;9:375-65.
45. Xu Y, Hu B, Choi AJ, et al. Unique DNA methylome profiles in CpG island methylator phenotype colon cancers. Genome Res 2012;22:283-91.
46. Feinberg AP, Vogelstein B. Hypomethylation distinguishes genes of some human cancers from their normal counterparts. Nature 1983;301:89-92.
47. Taft RJ, Pang KC, Mercer TR, et al. Non-coding RNAs: Regulators of disease. J Pathol 2010;220:126-39.
48. Dawson MA, Kouzarides T. Cancer epigenetics: From mechanism to therapy. Cell 2012;150:12-27.
49. Chodavarapu RK, Feng S, Bernatavichute YV, et al. Relationship between nucleosome positioning and DNA methylation. Nature 2010;466:388-92.
50. Harikrishnan KN, Chow MZ, Baker EK, et al. Brahma links the SWI/SNF chromatin-remodeling complex with MeCP2-dependent transcriptional silencing. Nat Genet 2005;37:254-64.
51. Reisman D, Glaros S, Thompson EA. The SWI/SNF complex and cancer. Oncogene 2009;28:1653-68.
52. Sansam CG, Roberts CWM. Epigenetics and cancer: Altered chromatin remodeling via Snf5 loss leads to aberrant cell cycle regulation. Cell Cycle 2006;5:621-4.
53. Sevenet N, Lellouch-Tubiana A, Schofield D, et al. Spectrum of hSNF5/INI1 somatic mutations in human cancer and genotypephenotype correlations. Hum Mol Genet 1999;8:2359-68.
54. Biegel JA, Zhou JY, Rorke LB, et al. Germ-line and acquired mutations of INI1 in atypical teratoid and rhabdoid tumors. Cancer Res 1999;59:74-9.
55. Roberts CWM, Biegel JA. The role of SMARCB1/INI1 in development of rhabdoid tumor. Cancer Biol Ther 2009;88:412-6.
56. Remo A, Zanella C, Molinari E, et al. Rhabdoid carcinoma of the colon, a distinct entity with a very aggressive behaviour. A case report, associated with a polyposis coli and review of the literature. Int J Surg Pathol 2012;2:185-90.
57. Pancione M, Di Blasi A, Sabatino L, et al. A novel case of rhabdoid colon carcinoma associated with a positive CpG island methylator phenotype and BRAF mutation. Hum Pathol 2011;42:1047-52.
58. Popat S, Hubner R, Houlston RS. Systematic review of microsatellite instability and colorectal cancer prognosis. J Clin Oncol 2005;23:609-18.
59. Lugli A, Zlobec I, Minoo P, et al. Prognostic significance of the wnt signalling pathway molecules APC, ®-catenin and E-cadherin in colorectal cancer-a tissue microarray-based analysis. Histopathology 2007;50:453-64.
60. Kalluri R, Weinberg RA. The basics of epithelialmesenchymal transition. J Clin Invest 2009;119:1420-8.
61. Clohessy JG, Pandolfi PP. β-tting on p63 as a Metastatic Suppressor. Cell 2009;137:28-30.
62. Ortega P, Moran A, De Juan C, et al. Differential Wnt pathway gene expression and E-cadherin truncation in sporadic colorectal cancers with and without microsatellite instability. Clin Cancer Res 2008;14:995-1001.
63. Suzuki H, Masuda N, Shimura T, et al. Nuclear ®-catenin expression at the invasive front and in the vessels predicts liver metastasis in colorectal carcinoma. Anticancer Res 2008;28:1821-30.
64. Horst D, Reu S, Kriegl L, et al. The intratumoral distribution of nuclear ®-catenin is a prognostic marker in colon cancer. Cancer 2009;115:2063-70.
65. Pancione M, Forte N, Fucci A, et al. Prognostic role of ®-catenin and p53 expression in the metastatic progression of sporadic colorectal cancer. Hum Pathol 2010;41:867-76.
66. Moreno-Bueno G, Peinado H, Molina P, et al. The morphological and molecular features of the epithelial-tomesenchymal transition. Nat Protoc 2009;4:1591-613.
67. Guarino M, Rubino B, Ballabio G. The role of epithelial-mesenchymal transition in cancer pathology. Pathology 2007;39:305-18.
68. Larriba MJ, Casado-Vela J, Pendas-Franco N, et al. Novel snail1 target proteins in human colon cancer identified byproteomic analysis. PLoS ONE 2010;5:e10221.
69. Moreno-Bueno G, Cubillo E, Sarrio D, et al. Genetic profiling of epithelial cells expressing E-cadherin repressors reveals a distinct role for snail, Slug, and E47 Factors in epithelial-mesenchymal transition. Cancer Res 2006;66:9543-56.
70. Amano M, Nakayama M, Kaibuchi K. Rhokinase/ROCK: A key regulator of the cytoskeleton and cell polarity. Cytoskeleton 2010;67:545-54.
71. GarcImmunohistochemical expression profile of ®-catenin, Ecadherin, P-cadherin, laminin-5©2 chain, and SMAD4 in colorectal serrated adenocarcinoma. Hum Pathol 2012;43:1094-102.
72. Pino MS, Kikuchi H, Zeng M, et al. Epithelial to mesenchymal transition is impaired in colon cancer cells with microsatellite instability. Gastroenterology 2010;138:1406-17.
73. Kang GH. Four molecular subtypes of colorectal cancer and their precursor lesions. Arch Pathol Lab Med 2011;135:698-703.
74. Bae JM, Kim MJ, Kimet JH, al. Differential clinicopathological features in microsatellite instability-positive colorectalcancers depending on CIMP status. Virchows Archiv 2011;459:55-63.
75. Jorissen RN, Gibbs P, Christie M, et al. Metastasisassociated gene expression changes predict poor outcomes in patients with Dukes stage B and C colorectal cancer. Clin Cancer Res 2009;15:7642-51.
76. Smith JJ, Deane NG, Wu F, et al. Experimentally derived metastasis gene expression profile predicts recurrence and death in patients with colon cancer. Gastroenterology 2010;138:958-68.
77. Loboda A, Nebozhyn MV, Watters JW, et al. EMT is the dominant program in human colon cancer. BMC Med Genomics 2011;4:9.
78. Prall F. Tumour budding in colorectal carcinoma. Histopathology 2007;50:151-62.
79. Karamitopoulou E, Lugli A, Panayiotides I, et al. Systematic assessment of protein phenotypes characterizing high-grade tumour budding in mismatch repair-proficient colorectal cancer. Histopathology 2010;57:233-43.
80. Zlobec I, Molinari F, Martin V, et al. Tumor budding predicts response to anti-EGFR therapies in metastatic colorectal cancer patients. World J Gastroenterol 2010;16:4823-31.
81. Zlobec I, Lugli A. Epithelial mesenchymal transition and tumor budding in aggressive colorectal cancer: Tumor budding as oncotarget. Oncotarget 2010;1:651-61.
82. Samowitz WS, Sweeney C, Herrick J, et al. Poor survival associated with the BRAF V600E mutation in microsatellitestable colon cancers. Cancer Res 2005;65:6063-70.
83. Legolvan MP, Taliano RJ, Resnick MB. Application of molecular techniques in the diagnosis, prognosis and management of patients with colorectal cancer: A practical approach. Hum Pathol 2012;43:1157-68.
84. Crowder CD, Sweet K, Lehman A, et al. Serrated polyposis is an underdiagnosed and unclear syndrome: The surgical pathologist has a role in improving detection. Am J Surg Pathol 2012;36:1178-85.
85. Giordano TJ. Molecular profiling and personalized predictive pathology: Challenge to the academic surgical pathology community. Am J Surg Pathol 2006;30:402-4.
86. Lauwers GY, Black-Schaffer S, Salto-Tellez M. Molecular pathology in contemporary diagnostic pathology laboratory: An opinion for the active role of surgical pathologists. Am J Surg Pathol 2010;34:115-7.